deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05553639

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Hookipa Biotech GmbH

Conditions Prostate Cancer Metastatic
Interventions HB-302/HB-301 Alternating 2-Vector Therapy
Updated 21 times since 2022 Last updated: Jun 10, 2024 Started: May 23, 2023 Primary completion: Apr 29, 2024 Completion: Apr 29, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Decision by the company to terminate the H-300-001 study early for non-safety related reasons.

Other terminated trials from Hookipa Biotech GmbH

More terminations from Hookipa Biotech GmbH

This PHASE1/PHASE2 trial investigates Prostate Cancer Metastatic and is currently terminated or withdrawn. Hookipa Biotech GmbH leads this study, which shows 21 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Status: Recruiting → Terminated · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 16 earlier versions

  1. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Feb 2023 — Mar 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  13. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  14. Dec 2022 — Jan 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  15. Nov 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  16. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hookipa Biotech GmbH
Data source: Hookipa Biotech GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations